
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.
Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.






